Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia starts earlier in males than females, with different treatments, and is linked to income, education, alcohol use, and mental health.

Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.

Chemotherapy caused a woman's permanent hair loss and early menopause.

Estrogen helps keep skin healthy and may make women look younger and more attractive.

Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.

Estrogen deficiency, like after menopause or certain surgeries, leads to faster skin aging and health issues.

Early diagnosis and surgery can improve symptoms of ovarian hyperthecosis in postmenopausal women.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Leydig cell tumors in the ovary can cause high testosterone and male traits in postmenopausal women but are treatable with surgery.

Tinea capitis in adults, especially postmenopausal Black women, needs prompt treatment with oral antifungals to avoid scarring.

A 46-year-old man showed symptoms of a rare condition usually seen in postmenopausal women, highlighting the need for dentist-dermatologist collaboration.

Frontal fibrosing alopecia can occur in children, not just postmenopausal women.

The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.

Most women had adequate essential elements except zinc, and lead levels were higher in peri-/post-menopausal women.

Men generally have higher blood pressure than premenopausal women, but postmenopausal women's blood pressure can surpass men's, and hormone therapy doesn't significantly help.

Frontal fibrosing alopecia can occur in children, not just postmenopausal women.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

A 46-year-old man was diagnosed with frontal fibrosing alopecia, a condition usually seen in postmenopausal women.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Frontal fibrosing alopecia causes hair loss along the frontal hairline, mainly in postmenopausal women, and needs better treatments.

A 60-year-old man with a long-term balding condition also developed a rare hair loss condition usually seen in postmenopausal women.

Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.

The study concludes that early diagnosis of Frontal Fibrosing Alopecia is important, as it is often found in postmenopausal women, may be related to Lichen Planopilaris, and eyebrow hair loss is a common sign.

The review suggests more research is needed to understand Frontal fibrosing alopecia, a condition causing hairline recession in postmenopausal women.

Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.

Taking 1 mg of finasteride daily can increase hair count and improve hair appearance, but it may have side effects on sexual function and a potential risk of prostate cancer. It may not be effective for postmenopausal women unless taken in higher doses.

Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.

Telogen Effluvium (TE) significantly affects women due to stress and hormonal changes, requiring better public health policies and mental health support.

The document concludes that managing health issues like menopause, cardiovascular risk, and hair loss is crucial for promoting longevity in aging women.